(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated (131)I-metaiodobenzylguanidine ((131)I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Garaventa, A, Bellagamba, O, Piccolo, M S Lo, Milanaccio, C, Lanino, E, Bertolazzi, L, Villavecchia, G P, Cabria, M, Scopinaro, G, Claudiani, F, Bernardi, B De
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362971/
https://www.ncbi.nlm.nih.gov/pubmed/10604736
http://dx.doi.org/10.1038/sj.bjc.6694223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362971/
https://www.ncbi.nlm.nih.gov/pubmed/10604736
http://dx.doi.org/10.1038/sj.bjc.6694223

Ejemplares similares